Featured today by @MSKLibrary: Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 dx.doi.org/10.1200/JCO....

#BMTCTN1703 #PatientReportedOutcomes #QualityOfLife #TransplantResearch

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) result...

The hits keep rolling in with #BMTCTN1703 💪 ascopubs.org/doi/10.1200/...